Barinthus Biotherapeutics plc.

Barinthus Biotherapeutics plc. (ticker: BRNS) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of BRNS's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. BRNS reported $0 in revenue and -$5.53M for the period ending 2025-12-31, with operating cash flow of -$3.37M. Cash and equivalents stood at $65.86M (down 33.6% year-over-year). Total assets of $92.14M exceed total liabilities of $25.66M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.